title: Response of fetal prostanoids, nitric oxide, and ductus arteriosus to the short- and long-term antenatal administration of celecoxib, a selective cyclo-oxygenase-2 inhibitor, in the pregnant rabbit.
abstract: OBJECTIVE
  The purpose of this study was to test the hypothesis that the maternal administration of therapeutic doses of celecoxib would not affect ductus arteriosus patency or alter renal and hepatic prostanoids in the fetal rabbit.
  
  
  METHODS
  Pregnant rabbits received celecoxib from 13 to 20 days (celecoxib-A), from 13-28 days (celecoxib-B), or vehicle from 13 to 28 days by gavage. Fetal serum and lung tissue were analyzed for nitric oxide oxidation products. Fetal plasma, liver, and kidney were analyzed for prostaglandin levels.
  
  
  RESULTS
  The ductus arteriosus was patent in both treatment groups. Celecoxib induced elevations of plasma prostaglandin E(2) production. In celecoxib-B liver and kidney, the 6-keto-prostaglandin F(1alpha) and prostaglandin F(2alpha) levels were increased, and the prostaglandin E(2) and thromboxane B(2) levels were decreased substantially.
  
  
  CONCLUSIONS
  This preliminary evaluation demonstrates that the maternal administration of celecoxib does not influence fetal ductus arteriosus patency adversely in rabbits.
authors.affiliation: Division of Maternal-Fetal Medicine, Women's Hospital, Long Beach Memorial Medical Center, 2801 Atlantic Avenue, Long Beach, CA 90801-1428, USA.
authors.forename: Nicole
authors.initials: N
authors.lastname: Hausman
authors.forename: Kay
authors.initials: K
authors.lastname: Beharry
authors.forename: Kenji
authors.initials: K
authors.lastname: Nishihara
authors.forename: Yasir
authors.initials: Y
authors.lastname: Akmal
authors.forename: Yuri
authors.initials: Y
authors.lastname: Stavitsky
authors.forename: Tamerou
authors.initials: T
authors.lastname: Asrat
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004334:Drug Administration Schedule; D004373:Ductus Arteriosus / Q000187:drug effects*; D005260:Female; D005333:Fetus / Q000187:drug effects; D009569:Nitric Oxide / Q000032:analysis* / Q000378:metabolism; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects*; D011336:Probability; D011453:Prostaglandins / Q000032:analysis* / Q000378:metabolism; D011720:Pyrazoles; D011817:Rabbits; D012016:Reference Values; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D013449:Sulfonamides / Q000494:pharmacology*
chemical_list: D016861:Cyclooxygenase Inhibitors; D011453:Prostaglandins; D011720:Pyrazoles; D013449:Sulfonamides; D009569:Nitric Oxide; D000068579:Celecoxib